Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mesalamine-associated thrombocytopenia.

R J Farrell1, M A Peppercorn, S N Fine

  • 1Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.

The American Journal of Gastroenterology
|August 13, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same author

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.

Alimentary pharmacology & therapeutics·2018
Same author

The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.

Alimentary pharmacology & therapeutics·2014
Same author

Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines.

Alimentary pharmacology & therapeutics·2014
Same author

The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method.

Alimentary pharmacology & therapeutics·2013
Same author

Macrophages promote epithelial repair through hepatocyte growth factor secretion.

Clinical and experimental immunology·2013

Mesalamine, a common ulcerative colitis treatment, can cause severe thrombocytopenia (low platelets) in rare cases. Regular blood monitoring is crucial for patients on mesalamine therapy.

Area of Science:

  • Gastroenterology
  • Hematology
  • Clinical Pharmacology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • Mesalamine (5-aminosalicylic acid) is a primary treatment for UC.
  • Sulfasalazine, a related drug, is known for causing serious blood disorders.

Observation:

  • A 25-year-old woman with UC developed significant thrombocytopenia during oral mesalamine treatment.
  • Thrombocytopenia recurred upon rechallenge with mesalamine, suggesting causality.
  • Previous reports of mesalamine-induced hematological toxicity lacked rechallenge confirmation.

Findings:

  • This case demonstrates mesalamine can idiosyncratic ally cause marked thrombocytopenia.
  • Rechallenge confirmed the causal link between mesalamine and thrombocytopenia.

Related Experiment Videos

  • The study differentiates drug-induced toxicity from potential autoimmune contributions of IBD.

    • Implications:

    • Mesalamine, like sulfasalazine, carries a risk of serious hematological toxicity.
    • Routine complete blood count monitoring is recommended for all patients on mesalamine.
    • This highlights the importance of considering drug-induced thrombocytopenia in IBD patients presenting with low platelets.